Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New studies offer evidence that an unexpected virus plays a role—but it needs a helper.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
There is a strong association between the prevalence of the virus among adults and its prevalence among children.
Ninety-seven percent of the children were cured of hepatitis C.
The U.S. FDA announced the approval of Mavyret, the first treatment for all hepatitis C genotypes in children ages 12 to 17.
A look at the latest news and research on the subject of children with viral hepatitis.
The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.
Rick Nash’s journey, born with Hep C, six treatments for Hepatitis C (HCV,) one transplant, and lots of friends and family.
The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Weight-based Harvoni treatment cured almost almost all of a small group of very young people.
At one hospital in Pittsburgh, the rate of pregnant women with hepatitis C seen for delivery rose 60 percent in eight years.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
The surgical practice is common in the United Kingdom but rare in the United States.
A study found that young people treated with biologic drugs for inflammatory bowel disease or various rheumatologic conditions were at risk.
The single-tablet regimen was just approved for adolsecent pediatric use in the United States.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.